Combined Therapeutics continues to strengthen its Intellectual Property position, supported by four solid patent families protecting our MOP platform across key markets. Our granted U.S. patents provide a strong commercial... read more →
CTx and Boston Children’s Hospital have completed studies evaluating two proprietary mRNA MOP-based adjuvants in combination with a commercially available recombinant influenza vaccine (Flublok®, Sanofi) in adult and elderly mice.... read more →
Combined Therapeutics will participate in the 2nd Annual Meeting in Coronado, California, from September 16–18, 2025.
We are pleased to announce that Robert Langer, Sc.D., has rejoined the Board of Directors of Combined Therapeutics in August 2025. His guidance and expertise will continue to be invaluable... read more →
CTx is proud to announce its membership in the Alliance for mRNA Medicine (AMM). By joining this global network of leading innovators in mRNA science, CTx reinforces its commitment to... read more →